ReShape Lifesciences® Announces Pricing of $3.0 Million Public Offering
September 29, 2023 12:30 ET
|
ReShape Lifesciences Inc
IRVINE, Calif., Sept. 29, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the pricing of...
ReShape Lifesciences® Announces Participation in the LD Micro Main Event XVI
September 22, 2023 08:31 ET
|
ReShape Lifesciences Inc
IRVINE, Calif., Sept. 22, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Paul...
ReShape Lifesciences® Signs Exclusive License Agreement With Biorad Medisys for Obalon® Gastric Balloon System
September 21, 2023 08:31 ET
|
ReShape Lifesciences Inc
IRVINE, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the signing...
ReShape Lifesciences® Significantly Strengthens Patent Portfolio Related to its Obalon® Balloon System
September 19, 2023 08:31 ET
|
ReShape Lifesciences Inc
IRVINE, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the...
ReShape Lifesciences® Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ Device
September 14, 2023 08:31 ET
|
ReShape Lifesciences Inc
IRVINE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the...
ReShape Lifesciences® Reports Second Quarter Ended June 30, 2023 Financial Results and Provides Corporate Update
August 07, 2023 16:05 ET
|
ReShape Lifesciences Inc
Company Executing Its Plan for Growth; Achieves Continued Improvement in Operational Effectiveness Reducing Second Quarter Operating Expenses by 53% Compared to Second Quarter of 2022 ...
ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2023 and Provide Corporate Update
August 03, 2023 16:05 ET
|
ReShape Lifesciences Inc
IRVINE, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will...
ReShape Lifesciences® Signs Preferred Partner Agreement With Hive Medical for Lead Optimization Software
June 29, 2023 08:31 ET
|
ReShape Lifesciences Inc
IRVINE, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the signing...
ReShape Lifesciences® Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the ASMBS 2023 Annual Meeting
June 28, 2023 08:31 ET
|
ReShape Lifesciences Inc
IRVINE, Calif., June 28, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today presented data on its...
ReShape Lifesciences® Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0
June 26, 2023 16:05 ET
|
ReShape Lifesciences Inc
IRVINE, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the submission...